Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist that Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models
Menée sur des lignées cellulaires de plusieurs types de cancer et à l'aide de xénogreffes, cette étude met en évidence l'activité antitumorale d'un peptide cyclique appelé LY2510924, un antagoniste sélectif de CXCR4
Emerging evidence demonstrates that SDF-1 and CXCR4, a chemokine and chemokine receptor pair, play important roles in tumorigenesis. In this report, we describe a small cyclic peptide, LY2510924, which is a potent and selective CXCR4 antagonist currently in phase II clinical studies for cancer. LY2510924 specifically blocked SDF-1 binding to CXCR4 with IC50 value of 0.079 nM, and inhibited SDF-1-induced GTP binding with Kb value of 0.38 nM. In human lymphoma U937 cells expressing endogenous CXCR4, LY2510924 inhibited SDF-1-induced cell migration with IC50 value of 0.26 nM and inhibited SDF-1/CXCR4-mediated intracellular signaling. LY2510924 exhibited a concentration-dependent inhibition of SDF-1-stimulated phospho-ERK and phospho-Akt in tumor cells. Biochemical and cellular analyses revealed that LY2510924 had no apparent agonist activity. Pharmacokinetic analyses suggested that LY2510924 had acceptable in vivo stability and a pharmacokinetic profile similar to a typical small molecular inhibitor in pre-clinical species. LY2510924 showed dose-dependent inhibition of tumor growth in human xenograft models developed with non-Hodgkin's lymphoma, renal cell carcinoma, lung, and colon cancer cells that express functional CXCR4. In MDA-MB-231, a breast cancer metastatic model, LY2510924 inhibited tumor metastasis by blocking migration/homing process of tumor cells to the lung and by inhibiting cell proliferation after tumor cell homing. Collectively, the preclinical data support further investigation of LY2510924 in clinic studies for cancer.
http://mct.aacrjournals.org/content/early/2014/12/12/1535-7163.MCT-14-0850.abstract